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A speciﬁc small-molecule inhibitor of p97 would provide an im-
portant tool to investigate diverse functions of this essential ATPase
associated with diverse cellular activities (AAA) ATPase and to eval-
uate its potential to be a therapeutic target in human disease. We
carried out a high-throughput screen to identify inhibitors of p97
ATPase activity. Dual-reporter cell lines that simultaneously express
p97-dependent and p97-independent proteasome substrates were
used to stratify inhibitors that emerged from the screen. N2,N4-
dibenzylquinazoline-2,4-diamine (DBeQ) was identiﬁed as a selec-
tive, potent, reversible, and ATP-competitive p97 inhibitor. DBeQ
blocks multiple processes that have been shown by RNAi to depend
on p97, including degradation of ubiquitin fusion degradation and
endoplasmic reticulum-associated degradation pathway reporters,
as well as autophagosome maturation. DBeQ also potently inhibits
cancer cell growth and is more rapid than a proteasome inhibitor at
mobilizing the executioner caspases-3 and -7. Our results provide
a rationale for targeting p97 in cancer therapy.
apoptosis | autophagy | unfolded protein response
The AAA (ATPase associated with diverse cellular activities)ATPase p97 is conserved across all eukaryotes and is essen-
tial for life in budding yeast (1) and mice (2). p97 was ﬁrst linked
to the ubiquitin–proteasome system (UPS) through its role in the
turnover of ubiquitin−β-galactosidase fusion proteins via the
“ubiquitin fusion degradation” (UFD) pathway (3). Since then,
p97 has been shown to play a critical role in the degradation of
misfolded membrane and secretory proteins (4) and has also
been linked to a broad array of cellular processes, including
Golgi membrane reassembly (5), membrane transport (6), reg-
ulation of myoﬁbril assembly (7), cell division (8), formation of
protein aggregates (9), and autophagosome maturation (10, 11).
The broad range of cellular functions for p97 is thought to derive
from its ability to unfold proteins or disassemble protein com-
plexes, but the detailed mechanism of how p97 works and is
linked to speciﬁc cellular processes remains largely unknown.
The structure of p97 comprises three domains: an N-terminal
domain that recruits adaptors/substrate speciﬁcity factors, fol-
lowed by two ATPase domains, D1 and D2 (12, 13). p97 mono-
mers assemble to form a homohexamer that is thought to provide
a platform for transduction of chemical activity into mechanical
force that is applied to substrate proteins. The D1 domain
mediates hexamerization (14) and has very low ATPase activity
(15). Most of the ATPase activity is contributed by the D2 do-
main, which is thought to underlie p97’s function as a mechano-
chemical transducer (16).
The mechanochemical activity of p97 is linked to substrate
proteins by an array of 13 UBX (ubiquitin regulatory X) domain
adapters that bind the N-terminal domain of p97 (17), as well as
the non-UBX domain adaptors Ufd1 and Npl4 (18). The func-
tions and mechanisms of action of these different p97–adaptor
complexes remain poorly understood. Recently our laboratory
reported a proteomic analysis of UBX cofactors and revealed
their interactions with a large number of E3 ligases and a cyto-
solic substrate, HIF-1α, whose interaction with p97 is mediated
by UBXD7 (19). Whereas all UBX proteins interact with p97,
only those containing a ubiquitin-associated domain associate
with ubiquitin conjugates (19). Thus, some p97–UBX complexes
may have functions that do not involve ubiquitin.
A major limitation to current studies on the biological functions
of p97/Cdc48 is that there is no method to rapidly shut off its
ATPase activity. The available temperature-sensitive (ts) mutants
of yeast Cdc48 require long incubations to fully extinguish their
activities, and the molecular bases for their effects are not known.
Given the range of cellular processes in whichCdc48 participates, it
is difﬁcult to determinewhether any particular phenotype observed
in theexistingmutants is due toadirect or indirect effect.Moreover,
inhibition of p97 activity in animal cells by siRNA or expression of
a dominant-negative version is challenged by its high abundance
and is not suited to evaluating proximal phenotypic effects of p97
loss of function. Therefore, a speciﬁc p97 inhibitor would be
a valuable research tool to investigate p97 function in cells.
Results
High-Throughput Screening to Identify p97 Small-Molecule Inhibitors.
The availability of a powerful suite of high-throughput screening
(HTS)-compatible assays to monitor p97 function in cells coupled
with the limitations of existing p97 inhibitors (SI Results) en-
couraged us to pursue development of a potent, selective, and
reversible p97 inhibitor that works by a deﬁned mechanism of
action. To facilitate HTS, a p97 ATPase assay was devised that
relied on using luciferase to measure the amount of ATP that
remained after incubation with p97. This assay was miniaturized
to a 1,536-well format and used to screen two libraries. Re-
combinant puriﬁed p97 was ﬁrst screened against a library of
16,000 compounds (at 10 μMeach; 16KHTS) from theMaybridge
Hitﬁnder Collection and then against 218,117 compounds (at
8 μM each; 218K HTS) from the National Institutes of Health
Molecular Libraries SmallMolecule Repository. In the 218KHTS
(PubChem AID1481), 925 primary hits were identiﬁed, 759 of
which were retested in triplicate to conﬁrm activity, yielding 333
active compounds (PubChem AID1517). Fifty-four of these that
inhibited activity by ≥50% at 8 μM were subjected to 10-point
titration, yielding ﬁve active compounds with IC50 ≤50 μM
(PubChem AID1534). Subsequent manual retesting of selected
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compounds suggested that AID1534 yielded high IC50 values for
compound potency (i.e., low inhibitory activity). IC50 values from
AID1534 and themanual ATPase assay are presented in Table S1.
Identiﬁcation of DBeQ as a Selective and Potent p97 Inhibitor. The
top compounds to emerge from HTS were next tested for their
ability to retard degradation of the UFD pathway and p97-
dependent substrate UbG76V-GFP in a cell-based assay (20). On
the basis of the results from this assay (Table S1), we narrowed
our focus to 10 compounds (Table 1) that inhibited p97 ATPase
with IC50 <10 μM in the manual ATPase assay and inhibited
degradation of UbG76V-GFP with an IC50 <10 μM. To evaluate
the selectivity of the top 10 compounds for targeting p97 in cells as
opposed to other ATPases that are generally required for UPS
function (e.g., E1 enzyme and the six AAA ATPase subunits of
the 26S proteasome), we next assayed them for their ability to
inhibit degradation of the p97-independent proteasome sub-
strates ODD-Luc (oxygen-dependent degradation domain of
HIF1α fused to luciferase) and Luc-ODC (luciferase fused to the
ubiquitin-independent degradation domain of ornithine decar-
boxylase) (21, 22) (Table 1). ODD-Luc is targeted to the pro-
teasome via the CRL2VHL ubiquitin ligase pathway, whereas Luc-
ODC is degraded by the proteasome in a manner that is in-
dependent of ubiquitination (23). Some of the compounds could
not be evaluated with the luciferase-based substrates because they
interfered with measurement of luciferase activity. To classify
these compounds, Western blot analysis of ODD-Luc turnover
was performed. Compounds 3, 4, 5, 7, and 8 blocked ODD-Luc
degradation to a similar extent as MG132 (a reversible protea-
some inhibitor) or PYR41 (an E1 inhibitor) (24) (Fig. 1A), sug-
gesting that they inhibited at least one component of the UPS
in addition to p97. Of the top 10 compounds, only compound 1
was more than 10-fold less potent in blocking ODD-Luc deg-
radation compared with UbG76V-GFP degradation. As a further
test of the selectivity of this compound we evaluated its ability
to inhibit AAA ATPase activity of puriﬁed N-ethylmaleimide–
sensitive factor (NSF) (25) and the ATP-dependent chymotryptic
activity of 26S proteasome (26). Compound 1 [which we have
renamed asN2,N4-dibenzylquinazoline-2,4-diamine (DBeQ)] was
at least 50-fold less potent toward these enzymes (Fig. 1B).
Inhibition of p97 by DBeQ Is Reversible, ATP-Competitive, and Not
Due to Colloid Formation. The D2 ATPase domain of p97 contains
a reactive cysteine (Cys522) in the ATP-binding pocket (27).
Because most of the top 10 hits shown in Table 1 contained
electrophilic moieties, we further evaluated their mechanism of
action by assaying their ability to inhibit the ATPase activity of
puriﬁed C522A-p97. The reduced activity of compounds 3
Table 1. Top 10 hits from two HTS screens for p97 inhibitors
Compound
no. and ID†
Assay IC50 (μM)*
Cell-based
degradation assay ATPase activity
UbG76V-GFP ODD-Luc Luc-ODC WT C522A
(1) CID16472035
CID676352
2.6 ± 0.3 56 ± 14 45 ± 11 1.5 ± 0.4 1.6 ± 0.3
2.3 ± 0.5‡ 1.6 ± 0.2‡
(2) CID886813 9.0 ± 1.3 43 ± 22 >30 3 ± 0.8 2 ± 0.2
13 ± 2‡ 1.2 ± 0.5‡
(3) JFD03665 1.1 ± 0.5 4.4 ± 1.0 NM 0.26 ± 0.05 8 ± 2
(4) CID6763 1.3 ± 0.5 3.3 ± 0.9 NM 3.5 ± 1.3 ND
(5) JFD02342 3.4 ± 1.0 5.2 ± 1.8 11 ± 4 0.2 ± 0.02 10 ± 4
(6) CID934321 3.6 ± 0.7 18 ± 8 NM 1.3 ± 0.2 12 ± 1
(7) S09756 5.0 ± 1.0 17 ± 4 NM 0.8 ± 0.08 20 ± 8
(8) JFD00597 6.6 ± 1.9 NM NM 6.1 ± 0.8 44 ± 12
(9) SEW05182 7.5 ± 2.9 NM NM 13 ± 1 30 ± 5
(10) CID1109468 10 ± 2 NM NM 2 ± 0.3 3 ± 0.2
NM, not measured due to interference with luciferase activity.
*Measurements were carried out in triplicate and the result expressed as
mean ± SE.
†Compounds with PubChem CID number are hits from the National Institutes
of Health Molecular Libraries Small Molecule Repository. All other com-
pounds are from the Maybridge HitFinder collection.
‡IC50 values of the resynthesized hits (SI Methods).
Fig. 1. DBeQ (1) is a reversible and selective inhibitor of p97. (A) Western
blot assays to evaluate speciﬁcity of the top 10 hits to emerge from HTS.
HeLa cells that stably expressed UbG76V-GFP and ODD-Luc were treated with
MG132, washed, and then incubated in the presence of CHX, plus test
compound for 2 h before harvest. Samples were immunoblotted to detect
ODD-Luc. The Ponceau S-stained ﬁlter serves as a loading control. The high
level of remaining antigen in lane 2 indicates that MG132 largely blocked
ODD-Luc degradation, whereas the relatively low level in lane 3 indicates
that 20 μM DBeQ failed to prevent ODD-Luc proteolysis. (B) Inhibition of
ATPase activity of p97 (diamonds), NSF (circles), or the ATP-dependent chy-
motryptic activity of 26S proteasome (triangles) by DBeQ. (C) Reversibility of
compound inhibition was determined by ﬁrst accumulating UbG76V-GFP in
the presence of MG132 (4 μM for 1 h), washing out MG132 and exposing
cells to CHX plus test compound for 2 h, and then washing out test com-
pound and monitoring decay of GFP signal in CHX for 0–4 h. (D) Lineweaver-
Burk plot of the competitive inhibition of p97 ATPase activity by DBeQ.
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through 9 toward C522A-p97 suggested that electrophilic attack
of Cys522 was indeed critical for the full potency of these com-
pounds (Table 1). As a test of reversibility in vivo, we evaluated
whether UbG76V-GFP degradation resumed upon washout of
inhibitor. Whereas UbG76V-GFP was degraded after washing out
MG132, it remained stable after preincubation with the covalent
inhibitors YU101 (a proteasome inhibitor) (28) or PYR41 (Fig.
1C). Given that all compounds except for DBeQ (compound 2
was not tested) exhibited at least partial irreversibility at con-
centrations <10 × IC50, we suggest that the mechanism of in-
hibition by compounds 3–9 was at least partially irreversible (Fig.
1C). Interestingly, the previously described p97 inhibitor EerI
(29) was also found to be irreversible.
On the basis of its favorable combination of potency, selectivity,
and reversibility, we nominated DBeQ for further characteriza-
tion. To determine the mechanism by which DBeQ inhibited p97
ATPase, we evaluated rates of ATP hydrolysis at different con-
centrations of ATP and DBeQ. DBeQ inhibited p97 competi-
tively with respect to ATP, with a Ki of 3.2 ± 0.4 μM (Fig. 1D),
suggesting that it binds to the active site of the D2 domain. It has
been reported that some HTS hits form colloids that cause non-
speciﬁc enzyme inhibition (30). To investigate whether DBeQ
acts in this manner, we performed dynamic light scattering anal-
ysis (Fig. S1 A–E). At a concentration of DBeQ (11 μM) that
causes nearly complete inhibition of ATPase activity, no aggre-
gation was detected (Fig. S1D). Moreover, inhibition of p97 by
DBeQ was not affected by 0.01% Triton X-100 (Fig. S1F).
DBeQ Does Not Exhibit Activity Toward Protein Kinases. The quina-
zoline scaffold at the core of DBeQ is found in compounds that
inhibit protein kinases (31). To uncover potential off-target ef-
fects of DBeQ on protein kinases, we evaluated DBeQ using an
activity-based proteomics platform (KiNativ; ActivX Biosciences).
This assay measures the ability of small molecules to inhibit the
covalent labeling of protein kinases by a broadly reactive ATP
acyl-phosphate probe directly in native cell lysates. As a positive
control, we carried out parallel analyses with a known protein ki-
nase inhibitor based on the pyrazolopyrimidine scaffold (32). The
results from these analyses are presented in Dataset S1. Re-
markably, DBeQ (15 μM) did not exhibit appreciable inhibition of
labeling of any of the ≈170 kinases that were evaluated, whereas
pyrazolopyrimidine exhibited>50% inhibition of 13 protein kinases
when tested at the same concentration.
Evaluation of DBeQ in ERAD and Autophagy Pathways. Because p97
has most commonly been studied in the context of endoplasmic
reticulum-associated degradation (ERAD) (6), we sought to eval-
uate the impact of DBeQ on the ERAD reporter TCRα-GFP (α
chain of the T-cell receptor fused to GFP). TCRα-GFP overex-
pressed in non-T cells inserts into the endoplasmic reticulum but
behaves as an unfolded protein and is degraded by the proteasome
in a p97-dependent manner (33). TCRα-GFP accumulation upon
p97 depletion was conﬁrmed by ﬂow cytometry and Western blot
(Fig. S2 A and B). DBeQ potently blocked degradation of TCRα-
GFP at 10 μM (Fig. 2A and Fig. S2C). Blockade of ERAD ulti-
mately leads to activation of the unfolded protein response (UPR),
which contributes to the anticancer effects of bortezomib (34). A
well-established marker of the UPR is the transcription factor
CHOP (GADD153), whichmediates endoplasmic reticulum stress-
induced apoptosis (35). CHOP is up-regulated in bortezomib-
treated cells within 4 h (34). CHOP accumulated in the nucleus and
membrane-enriched fractions of HeLa cells that were either de-
pleted of p97 (Fig. 2B, lane 4) or expressed an ATPase-inactive
mutant (Fig. 2B, lane 8). CHOP induces apoptosis in part by down-
regulating p21 (36). Consistent with this ﬁnding, we also observed
a decrease of p21 protein level in cells that were depleted of p97 or
overexpressed the ATPase-inactive mutant (Fig. 2B, lanes 2, 4, and
8). DBeQ induced CHOP within 3 h in a concentration-dependent
manner (Fig. 2C, lanes 4–6) but did not increase p21 level (Fig. S3,
lanes 3 and 6). By contrast,MG132 increased both CHOP (Fig. 2C,
lane1) and p21 (Fig. S3, lanes 2 and 5), consistent with the docu-
mented instability of p21 (37).
In addition to the well-characterized function of p97 in ERAD,
p97 plays an important role in autophagy (10, 11). Inhibition of
p97’s function by siRNA or expression of dominant-negative
mutants leads to a defect in autophagosome maturation that is
manifest as a net conversion of the autophagosome marker LC3-I
to the lipidated LC3-II species (10, 11). Consistent with this, we
observed 30- to 40-fold accumulation of LC3-II in both cytosol
and nucleus/membrane-enriched fractions of p97-depleted HeLa
cells (Fig. S4). DBeQ likewise induced a strong accumulation of
LC3-II in the nucleus plus membrane-enriched (Fig. 2C, lanes 4–
6) and cytosolic (Fig. 3A, lane 3) fractions. LC3-II can accumulate
either because DBeQ stimulates basal autophagy (i.e., accelerates
conversion of LC3-I to LC3-II) or, like p97 depletion, blocks
a late step in autophagosome maturation. To distinguish between
these possibilities, we evaluated the effect of DBeQ on cells in
which autophagy was induced by nutrient starvation. In nutrient-
starved cells treated with DMSO alone or a low dose of DBeQ
(2.5 μM), LC3-I was rapidly converted to LC3-II and degraded
(Fig. 3B). By contrast, in nutrient-starved cells treated with 15 μM
DBeQ, LC3-II was markedly stabilized. Next, we examined the
effect of DBeQ on LC3-II level in combination with known
inhibitors of autophagy. Coincubation or sequential treatment
with baﬁlomycin A1 (Baf) and DBeQ did not result in a signiﬁ-
cant increase in LC3-II compared with the sample treated with
only Baf (Fig. 3C). A similar observation was made with chloro-
quine (CHQ; Fig. 3D, lanes 4 and 5). Taken together, these data
indicate that DBeQ acted by blocking autophagic degradation of
LC3-II instead of inducing autophagy.
DBeQ Rapidly Induces Caspases and Inhibits Cell Proliferation. In a
prior study, DBeQ was identiﬁed as a compound that more po-
tently induces apoptosis in human cancer cells compared with
noncancerous cells. However, the underlying mechanism was not
determined (38). In our hands, 10 μM DBeQ rapidly promoted
activation of the “executioner” caspases-3 and -7 in HeLa cells
(Fig. 4A). We benchmarked DBeQ by comparing it with the well-
characterized apoptosis inducer staurosporine (STS) (39) and the
procaspases-3 and -6 activator 1541 (40). STS induces executioner
caspases-3, -6, and -7 via both caspases-8 and -9 in the apoptotic
pathway (40, 41). DBeQ activated caspases-3 and -7 by twofold
within 2 h (Fig. 4B) but did not activate caspase-6 after 6 h (Fig.
4C). We next evaluated the impact of DBeQ on initiator cas-
pases-8 and -9. DBeQ activated the intrinsic caspase-9 apoptotic
pathway more than the extrinsic caspase-8 pathway, whereas STS
activated both pathways to a similar extent (Fig. 4 D and E).
Depletion of p97 by siRNA mimicked the effects of DBeQ on
caspase activation (Fig. 4F), suggesting that apoptosis induction
may be an “on-target” effect. Caspase activation by DBeQ was
blocked by the general caspase inhibitor [Z-VAD(OMe)FMK;
Fig. 4G], whereas accumulation of LC3-II was not affected (Fig.
3D, lane 3), suggesting that the block in autophagosome matu-
ration induced by DBeQ was not an indirect consequence of
caspase activation (42). Consistent with the speed of caspase
induction by DBeQ, we determined that it was insensitive to
cycloheximide (CHX) (Fig. 4G).
We next compared the antiproliferative activity of DBeQ and
MG132 on normal and cancerous cell lines after 48 h treatment
(Table 2). DBeQ was ﬁvefold more active against multiple mye-
loma (RPMI8226) cells than normal human fetal lung ﬁbroblasts
(MRC5), with HeLa and Hek293 cells showing intermediate
sensitivities. MG132 was 10- to 20-fold more potent than DBeQ at
blocking growth of all four cell lines tested, in keeping with its 10-
fold greater potency in blocking UbG76V-GFP degradation (22).
We next evaluated the time-dependence of caspase activation and
cellular viability for HeLa and RPMI8226 cells incubated with
DBeQ, STS, 1541, or MG132. For both cell lines, there was a good
correlation between the kinetics of caspases-3 and -7 activation
and cell death induced by DBeQ and STS (Fig. 4 H and I and Fig.
S5). Interestingly, in contrast to DBeQ, in a 20-h treatment
MG132 exhibited potent activity only against the RPMI8226 cells.
Thus, although MG132 is a more potent inhibitor of its intended
target, DBeQ is more effective at blocking cell growth upon tran-
sient exposure to drug. Strong mobilization of caspase activity by
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DBeQ seemed to be due primarily to caspase-3, because DBeQ
induced only modest activation of caspase-7 in caspase-3–deﬁcient
MCF7 cells (43) (Fig. S6A). Finally, consistent with our observation
that DBeQ induced caspases-3 and -7 activity even in the presence
of CHX (Fig. 4G), DBeQ mobilized caspases-3 and -7 activities
with equivalent kinetics in wild-type and p53−/−HCT116 cells (Fig.
S6 B and C), implying that p53-mediated gene transcription is not
required to induced cell death in response to DBeQ.
Discussion
Motivated by the value of a potent and selective inhibitor of the
AAA ATPase p97 as a basic research tool and as a potential
starting point for development of a novel cancer therapeutic, we
have carried out two HTS campaigns to identify small molecules
that inhibit p97 ATPase activity. Secondary screens with cell lines
that report on p97-dependent and -independent degradation (20)
allowed us to winnow the ﬁeld of candidate inhibitors to two re-
lated compounds (1 and 2) that acted reversibly and exhibited IC50
values of ≤10 μM both in vitro and in cells. The best compound, 1
(DBeQ), inhibited p97 ATPase and degradation of the p97-
dependent substrate UbG76V-GFP, with IC50 values of 1.5 μM and
2.6 μM, respectively, but had negligible effects on degradation of
p97-independent substrates and ATPase activity of the closely
related NSF.
DBeQ is active against two distinct classes of UPS substrates—
UFD and ERAD—that depend on p97 for their degradation.
Consistent with its effect on ERAD, DBeQ induces accumulation
of the UPR effector CHOP. By contrast, DBeQ has little effect
onODD-luciferase and luciferase-ODC, neither ofwhich depends
on p97 for degradation. Together, these results suggest that the
major target of DBeQ within the UPS is p97. Although the pro-
teasome contains sixAAAATPase subunits, DBeQdid not inhibit
proteasome-dependent degradation of the luciferase reporters,
nor did it inhibit ATP-dependent cleavage of Leu-Leu-Val-Tyr-
aminomethlycoumarin (LLVY-AMC) by puriﬁed proteasome.
Thus, DBeQmay be a useful tool to identify UPS substrates whose
degradation depends on p97. In addition to its role in theUPS, p97
has been linked to multiple other processes, which may or may not
involve ubiquitination (see the Introduction). To evaluate the
generality of DBeQ-mediated inhibition of p97 function, we in-
vestigated the impact ofDBeQonautophagy.Ashas been reported
for p97 depletion, DBeQ promoted accumulation of the autopha-
gic intermediate LC3-II. This observation suggests that DBeQmay
beuseful to study functions of p97 bothwithin and outside theUPS.
A remarkable feature of DBeQ is that it rapidly and potently
induced activation of executioner caspases and cell death.
Whereas a procaspase activator was reported to induce caspase
when applied to cells at 25 μM for 4–8 h (40), 10 μM DBeQ
mobilized substantial caspase activity within 2–5 h. Although the
proteasome inhibitor MG132 was more potent than DBeQ in
blocking cell growth in a 48-h incubation, the converse was true
upon briefer exposure to these drugs. This may be clinically sig-
niﬁcant. Proteasome inhibitors have shown strong single-agent
activity only in cancers of the hematopoietic lineage (44). By
contrast, cell lines derived from solid tumors can survive long (up
to 20-h) exposures to proteasome inhibitors, and perhaps as
a consequence, bortezomib has shown little clinical activity toward
solid tumors (44). The ability of DBeQ to induce rapid caspase
activation and cell death even in cell lines derived from solid
tumors suggests that p97 inhibition may be more efﬁcacious than
proteasome inhibition as a strategy for cancer chemotherapy.
We do not know the mechanism by which DBeQ elicits rapid
induction of executioner caspases. One possibility is that simul-
taneous suppression of two parallel mechanisms of protein
degradation accounts for the toxicity of p97 inhibitors. Not only
Fig. 2. DBeQ impairs the ERAD pathway. (A) Hek293 cells stably expressing
the ERAD reporter TCRα-GFP were used to determine effect of DBeQ on the
ERAD pathway. Cells were treated with drug as described in Fig. 1A, and GFP
intensity was determined by ﬂow cytometry at the indicated time points. (B)
HeLa cells were transfected with negative control siRNA (NC) or p97 siRNA
(10 nM) for 72 h (lanes 1–4) or with cDNAs encoding wild-type (WT) or
ATPase mutant (QQ) p97 for 24 h (lanes 5–8), and the levels and distributions
of the indicated proteins were determined by immunoblotting cytosolic
(Cyto) and nuclear plus membrane (NM) fractions. (C) HeLa cells were in-
cubated with 10 μM of MG132, 25 μM of CHX, or 5, 10, or 15 μM of DBeQ for
3 h, and the levels of CHOP and LC3 in the nuclear plus membrane (NM)
fractions were determined by immunoblotting.
Fig. 3. DBeQ impairs the autophagy pathway. (A) Cells were incubated with
20 μM of MG132 or DBeQ for 3 h, and cytosolic LC3 level was determined by
immunoblotting. The Ponceau S-stained ﬁlter serves as a loading control. (B)
Degradation of LC3-II was monitored in Earle’s balanced salt solution (EBSS)
nutrient-starvation medium for 0, 30, 120, or 240 min (lanes 1–4). DBeQ
(15 μM) completely stabilized LC3-II (lanes 5–7), whereas 2.5 μM DBeQ had
little effect (lanes 8–10). (C) Cells were incubated with DMSO (lane 1) or Baf
(0.25 μM, 5 h; lane 2) or Baf plus DBeQ (lanes 3 and 4) for 5 h or ﬁrst treated
with Baf for 2.5 h then exposed to DBeQ for an additional 2.5 h (lanes 5 and
6). The same experiments were carried out at 10 μM Baf (lanes 7–11). Lane
12 contains sample from cells treated with DBeQ (10 μM, 5 h) alone. All
treatments were evaluated by immunoblotting cell lysates with antibodies
to detect the indicated proteins. (D) Cells were treated with Z-VAD (25 μM),
Z-VAD plus DBeQ (15 μM), CHQ (20 μM), or CHQ plus DBeQ, followed by
immunoblotting cell extracts to detect the indicated proteins.
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is p97 required for autophagy and ERAD, but in yeast, Cdc48 is
required for rapid degradation of proteins that fail to mature
properly owing to heat or oxidative stress, pointing to a broad
role for p97 in multiple mechanisms of protein quality control
(45). The full impact of inhibition of ubiquitin-dependent pro-
tein degradation (e.g., by proteasome inhibitors) may normally
be mitigated by up-regulation of autophagy (46, 47). Simulta-
neous inhibition of proteasome and histone deacetylase 6
(HDAC6) [which is required for autophagy (48, 49)] results in
synergistic killing of multiple myeloma cells (50). Interestingly,
more than one dozen human clinical trials (www.clinicaltrials.
gov) combine bortezomib with the broad-spectrum HDAC in-
hibitor vorinostat, which is active toward HDAC6. Targeting p97
may provide an alternative route to achieving the same objective.
Cancer cells may be particularly sensitive to killing by suppres-
sion of protein degradation mechanisms, because they may ex-
hibit a heightened dependency on these mechanisms to clear an
elevated burden of quality-control substrates (51). For example,
some cancers produce high levels of a speciﬁc protein that is
a prominent quality-control substrate (e.g., Ig light chains in
multiple myeloma) (34, 52) or produce high levels of reactive
oxygen species (53), which can result in excessive protein damage
via oxidation. Alternatively, many cancer cells are aneuploid and
produce unbalanced levels of subunits of protein complexes,
which can heighten dependency on protein folding and clearance
mechanisms (54, 55). Finally, the burden of point and deletion
mutations in the cancer cell or an altered metabolic environment
may lead to an increased rate of protein misfolding or mis-
assembly (56).
An alternative possibility for why DBeQ induces rapid caspase
activation is that p97 may regulate the activity of factors in the
extrinsic or intrinsic signaling cascades that culminate in activation
of executioner caspases. DBeQ may impinge on maintenance of
inhibited caspase–IAP (inhibitor of apoptosis) complexes. Finally
it is possible that caspase activation and apoptosis are “off-target”
effects. However, p97 knockdown also induces caspases and cell
death, and a similar phenomenon has been reported for the ir-
reversible p97 inhibitor EerI (57). Together, these results suggest
that caspase signaling to cell death is an “on-target” effect of p97
inhibition. Future work will provide molecular insight into how
inhibition of p97 activity by DBeQ results in apoptosis and could
strengthen the rationale for a p97-targeted cancer therapeutic.
Methods
Materials and detailed methods are available in SI Methods.
Reporter Degradation Assay. Two dual reporter stable HeLa cell lines were
used and are described elsewhere (22). One expressed the UFD reporter
UbG76V-GFP (58) and ODD-Luc (21), and the second expressed UbG76V-GFP
and Luc-ODC (21).
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Fig. 4. DBeQ and depletion of p97 induce activation of caspases. (A) HeLa
cells were incubated with the indicated concentrations of 1541, DBeQ, or STS
for 4 h before determination of caspases-3 plus -7 activities in the cell extract.
(B) HeLa cells were incubatedwith 20 μMof 1541, 10 μMofDBeQ, or 2.5 μMof
STS for 2, 4, or 6 h before determination of caspases-3 plus -7 activities in
the cell extract. (C–E) Same as B, except caspases-6, -8, and -9 activities were
determined, respectively. (F) HeLa cells were transfectedwith negative control
siRNA (NC) or p97 siRNA (10 nM) for 72 h, after which the activities of the
indicated caspases were measured in total cell lysate. (G) HeLa cells were
incubated with the indicated concentrations of drugs for 3 h before de-
termination of caspases-3 plus -7 activities in total cell lysate. DBeQ plus CHX
were includedat 10 μMand100 μM, respectively. (H) HeLa cellswere incubated
with the indicated concentrations of drugs for 1, 2, 4, 6, 8, 9, or 21 h before
determination of caspases-3 plus -7 activities in total cell lysate. (I) Same as H,
except cellular viabilitywas determined using CellTiter-Glo after 3, 6, 8, or 20 h.
Table 2. Cytotoxicity of MG132 and DBeQ after 48 h treatment
Concentration (in μM) at which
growth is inhibited by 50% (GI50)*
Compound MRC-5† Hek293 HeLa RPMI8226‡
MG132 0.4 ± 0.1 0.2 ± 0.05 1.5 ± 0.3 0.14 ± 0.03
DBeQ 6.6 ± 2.9 4 ± 0.6 3.1 ± 0.5 1.2 ± 0.3
*Measurements were carried out in triplicate and the result expressed as
mean ± SE.
†Normal human fetal lung ﬁbroblast.
‡Multiple myeloma cell line.
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